Allergan Lumigan 0.01% Ophthalmic Solution Recall: Impurities Risk
Allergan recalls Lumigan 0.01% ophthalmic solution bottles with failed impurities specifications. This recall addresses potential degradation risks in the medication.
Lower-risk recall
Failed Impurities/Degradation Specifications
Contact the company
What happened, in plain English
Allergan is recalling Lumigan (bimatoprost ophthalmic solution) 0.01% 7.5 mL bottles due to failed impurities and degradation specifications. This could pose a risk of medication impurities affecting eye health. Read more at govinfonow.com/recall/41810-allergan-lumigan-0-01-ophthalmic-solution-recall-impurities-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41810-allergan-lumigan-0-01-ophthalmic-solution-recall-impurities-risk · Updated October 8, 2026 · FDA enforcement record: FDA #D-0667-2017
Cite this page
“Allergan Lumigan 0.01% Ophthalmic Solution Recall: Impurities Risk.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41810-allergan-lumigan-0-01-ophthalmic-solution-recall-impurities-risk. Based on FDA recall #D-0667-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0667-2017%22&limit=1).
Why it’s dangerous
The medication may contain impurities or degrade over time, potentially leading to eye irritation or other adverse effects. This issue occurs due to failure in the manufacturing specifications for the product.
Who’s affected
Prescription users of Lumigan 0.01% ophthalmic solution who received the specific bottle size and lot number are affected. Patients with glaucoma or eye pressure issues are most at risk.
How to tell if you have this one
Check for the 7.5 mL bottle labeled Lumigan 0.01% with the lot number 92577 and expiration date June 2018. This specific batch was recalled by Allergan.
- Brand
Allergan- Category
Drug
What to do — step by step
Check Product Details
Verify the product label for the 7.5 mL bottle, lot number 92577, and expiration date of June 2018.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 2.1 years after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0667-2017 (March 16, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0667-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.